Immunization with advanced glycation end products modified low density lipoprotein inhibits atherosclerosis progression in diabetic apoE and LDLR null mice

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Zhu, Lin ^a,b   He, Zhiqing ^a   Wu, Feng ^a,c   Ding, Ru ^a   Jiang, Qixia ^a   Zhang, Jiayou ^a   Fan, Min ^a   Wang, Xing ^a   Eva, Bengtsson ^d   Jan, Nilsson ^d   Liang, Chun ^a   Wu, Zonggui ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Chinese PLA 457th Hospital   (China)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Advanced glycation end products; Atherosclerosis; Diabetes; Immunization; Low density lipoprotein

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT MODIFIED LOW DENSITY LIPOPROTEIN CHOLESTEROL; ALUMINUM HYDROXIDE; CHOLESTEROL DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 10; PHOSPHATE BUFFERED SALINE; STREPTOZOCIN; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; AUTOANTIBODY; GLYCOSYLATED LIPOPROTEINS, LDL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROPROTECTIVE ACTIVITY; ATHEROSCLEROSIS; CELLULAR IMMUNITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ACTIVITY; ENZYME INHIBITION; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; LIMIT OF QUANTITATION; LIPID DIET; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; UPREGULATION; ANIMAL; C57BL MOUSE; DEFICIENCY; EXPERIMENTAL DIABETES MELLITUS; HYPERGLYCEMIA; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; AUTOANTIBODIES; DIABETES MELLITUS, EXPERIMENTAL; DISEASE PROGRESSION; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPERGLYCEMIA; IMMUNIZATION; LIPOPROTEINS, LDL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, LDL;

EID: 84920847396     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-014-0151-6     Document Type: Article

References (55)

1. Goldfine AB, Goldfine HL: Cardiology patient pages. Cardiovascular disease in the diabetic patient. Circulation 2003, 107:e14-e16.
2. de Jager SC, Kuiper J: Vaccination strategies in atherosclerosis. Thromb Haemost 2011, 106:796-803.
3. Suthers B, Hansbro P, Thambar S, McEvoy M, Peel R, Attia J: Pneumococcal vaccination may induce anti-oxidized low-density lipoprotein antibodies that have potentially protective effects against cardiovascular disease. Vaccine 2012, 30:3983-3985.
4. Tissot AC, Spohn G, Jennings GT, Shamshiev A, Kurrer MO, Windak R, Meier M, Viesti M, Hersberger M, Kundig TM, Ricci R, Bachmann MF: A VLP-based vaccine against interleukin-1alpha protects mice from atherosclerosis. Eur J Immunol 2013, 43:716-722.
5. Qi G, Li J, Wang S, Xin S, Du P, Zhang Q, Zhao X: A chimeric peptide of intestinal trefoil factor containing cholesteryl ester transfer protein B cell epitope significantly inhibits atherosclerosis in rabbits after oral administration. Peptides 2011, 32:790-796.
6. Koizumi Y, Kurita-Ochiai T, Oguchi S, Yamamoto M: Intranasal immunization with Porphyromonas gingivalis and atherosclerosis. Immunopharmacol Immunotoxicol 2009, 31:352-357.
7. de Carvalho JF, Pereira RM, Shoenfeld Y: Vaccination for atherosclerosis. Clin Rev Allergy Immunol 2010, 38:135-140.
8. Hauer AD, Habets KL, van Wanrooij EJ, de Vos P, Krueger J, Reisfeld RA, van Berkel TJ, Kuiper J: Vaccination against TIE2 reduces atherosclerosis. Atherosclerosis 2009, 204:365-371.
9. van Wanrooij EJ, de Vos P, Bixel MG, Vestweber D, van Berkel TJ, Kuiper J: Vaccination against CD99 inhibits atherogenesis in low-density lipoprotein receptor-deficient mice. Cardiovasc Res 2008, 78:590-596.
10. Laczik R, Szodoray P, Veres K, Szomjak E, Csipo I, Sipka S Jr, Shoenfeld Y, Szekanecz Z, Soltesz P: Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome. Lupus 2011, 20:730-735.
11. Habets KL, van Puijvelde GH, van Duivenvoorde LM, van Wanrooij EJ, de Vos P, Tervaert JW, van Berkel TJ, Toes RE, Kuiper J: Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice. Cardiovasc Res 2010, 85:622-630.
12. Schiopu A, Frendeus B, Jansson B, Soderberg I, Ljungcrantz I, Araya Z, Shah PK, Carlsson R, Nilsson J, Fredrikson GN: Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. J Am Coll Cardiol 2007, 50:2313-2318.
13. Yamagishi S, Nakamura K, Imaizumi T: Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabetes Rev 2005, 1:93-106.
14. Basta G, Schmidt AM, De Caterina R: Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004, 63:582-592.
15. Cai W, He JC, Zhu L, Peppa M, Lu C, Uribarri J, Vlassara H: High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 2004, 110:285-291.
16. Liang C, Ren Y, Tan H, He Z, Jiang Q, Wu J, Zhen Y, Fan M, Wu Z: Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products. Br J Pharmacol 2009, 158:1865-1873.
17. Sun C, Liang C, Ren Y, Zhen Y, He Z, Wang H, Tan H, Pan X, Wu Z: Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways. Basic Res Cardiol 2009, 104:42-49.
18. Cheng A, Dong Y, Zhu F, Liu Y, Hou FF, Nie J: AGE-LDL activates Toll like receptor 4 pathway and promotes inflammatory cytokines production in renal tubular epithelial cells. Int J Biol Sci 2013, 9:94-107.
19. Hodgkinson CP, Laxton RC, Patel K, Ye S: Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol 2008, 28:2275-2281.
20. Li F, Cai Z, Chen F, Shi X, Zhang Q, Chen S, Shi J, Wang DW, Dong N: Pioglitazone attenuates progression of aortic valve calcification via down-regulating receptor for advanced glycation end products. Basic Res Cardiol 2012, 107:306.
21. de Nigris F, Gallo L, Sica V, Napoli C: Glycoxidation of low-density lipoprotein promotes multiple apoptotic pathways and NFkappaB activation in human coronary cells. Basic Res Cardiol 2006, 101:101-108.
22. Virella G, Thorpe SR, Alderson NL, Derrick MB, Chassereau C, Rhett JM, Lopes-Virella MF: Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J Lipid Res 2004, 45:1859-1867.
23. Virella G, Thorpe SR, Alderson NL, Stephan EM, Atchley D, Wagner F, Lopes-Virella MF, Group DER: Autoimmune response to advanced glycosylation end-products of human LDL. J Lipid Res 2003, 44:487-493.
24. Yan J, Stringer SE, Hamilton A, Charlton-Menys V, Gotting C, Muller B, Aeschlimann D, Alexander MY: Decorin GAG synthesis and TGF-beta signaling mediate Ox-LDL-induced mineralization of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2011, 31:608-615.
25. Nivoit P, Wiernsperger N, Moulin P, Lagarde M, Renaudin C: Effect of glycated LDL on microvascular tone in mice: a comparative study with LDL modified in vitro or isolated from diabetic patients. Diabetologia 2003, 46:1550-1558.
26. Toma L, Stancu CS, Botez GM, Sima AV, Simionescu M: Irreversibly glycated LDL induce oxidative and inflammatory state in human endothelial cells; added effect of high glucose. Biochem Biophys Res Commun 2009, 390:877-882.
27. Markwell MA, Haas SM, Bieber LL, Tolbert NE: A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 1978, 87:206-210.
28. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, Stadtman ER: Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990, 186:464-478.
29. Sima AV, Botez GM, Stancu CS, Manea A, Raicu M, Simionescu M: Effect of irreversibly glycated LDL in human vascular smooth muscle cells: lipid loading, oxidative and inflammatory stress. J Cell Mol Med 2010, 14:2790-2802.
30. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG: Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010, 8:e1000412.
31. McEvoy RC, Andersson J, Sandler S, Hellerstrom C: Multiple low-dose streptozotocin-induced diabetes in the mouse. Evidence for stimulation of a cytotoxic cellular immune response against an insulin-producing beta cell line. J Clin Invest 1984, 74:715-722.
32. Fredrikson GN, Soderberg I, Lindholm M, Dimayuga P, Chyu KY, Shah PK, Nilsson J: Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 2003, 23:879-884.
33. Wortmann M, Schneider M, Pircher J, Hellfritsch J, Aichler M, Vegi N, Kolle P, Kuhlencordt P, Walch A, Pohl U, Bornkamm GW, Conrad M, Beck H: Combined deficiency in glutathione peroxidase 4 and vitamin E causes multiorgan thrombus formation and early death in mice. Circ Res 2013, 113:408-417.
34. Zhao H, Przybylska M, Wu IH, Zhang J, Siegel C, Komarnitsky S, Yew NS, Cheng SH: Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 2007, 56:1210-1218.
35. Soran H, Durrington PN: Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol 2011, 22:254-261.
36. Wigren M, Bengtsson D, Duner P, Olofsson K, Bjorkbacka H, Bengtsson E, Fredrikson GN, Nilsson J: Atheroprotective effects of Alum are associated with capture of oxidized LDL antigens and activation of regulatory T cells. Circ Res 2009, 104:e62-e70.
37. Vay D, Vidali M, Allochis G, Cusaro C, Rolla R, Mottaran E, Bellomo G, Albano E: Antibodies against advanced glycation end product Nepsilon-(carboxymethyl)lysine in healthy controls and diabetic patients. Diabetologia 2000, 43:1385-1388.
38. Turk Z, Ljubic S, Turk N, Benko B: Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus. Clin Chim Acta 2001, 303:105-115.
39. Zhang Y, Lapidos KA, Gal-Moscovici A, Sprague SM, Ameer GA: A receptorbased bioadsorbent to target advanced glycation end products in chronic kidney disease. Artif Organs 2014, 38:474-483.
40. Fukushima Y, Daida H, Morimoto T, Kasai T, Miyauchi K, Yamagishi S, Takeuchi M, Hiro T, Kimura T, Nakagawa Y, Yamagishi M, Ozaki Y, Matsuzaki M, JAPAN-ACS Investigators: Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study. Cardiovasc Diabetol 2013, 12:5.
41. van Eupen MG, Schram MT, Colhoun HM, Scheijen JL, Stehouwer CD, Schalkwijk CG: Plasma levels of advanced glycation endproducts are associated with type 1 diabetes and coronary artery calcification. Cardiovasc Diabetol 2013, 12:149.
42. Younis N, Charlton-Menys V, Sharma R, Soran H, Durrington PN: Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro. Atherosclerosis 2009, 202:162-168.
43. Hermansson A, Ketelhuth DF, Strodthoff D, Wurm M, Hansson EM, Nicoletti A, Paulsson-Berne G, Hansson GK: Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med 2010, 207:1081-1093.
44. Wang C, Yu Y, Zhang X, Li Y, Kou C, Li B, Tao Y, Zhen Q, He H, Kanu JS, Huang X, Han M, Liu Y: Awareness, treatment, control of diabetes mellitus and the risk factors: survey results from Northeast China. PLoS One 2014, 9:e103594.
45. Stessman J, Jacobs JM: Diabetes Mellitus, Physical Activity, and Longevity Between the Ages of 70 and 90. J Am Geriatr Soc 2014. in Press. doi:10.1111/jgs.12930.
46. Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S: Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol 2013, 12:125.
47. Yi B, Hu X, Wen Z, Zhang T, Cai Y: Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits hyperglycemia-induced apoptosis in myocytes by suppressing receptor for advanced glycation end products expression. Exp Ther Med 2014, 8:1185-1190.
48. Masola V, Gambaro G, Tibaldi E, Onisto M, Abaterusso C, Lupo A: Regulation of heparanase by albumin and advanced glycation end products in proximal tubular cells. Biochim Biophys Acta 1813, 2011:1475-1482.
49. Qin Q, Niu J, Wang Z, Xu W, Qiao Z, Gu Y: Heparanase induced by advanced glycation end products (AGEs) promotes macrophage migration involving RAGE and PI3K/AKT pathway. Cardiovasc Diabetol 2013, 12:37.
50. Duner P, To F, Beckmann K, Bjorkbacka H, Fredrikson GN, Nilsson J, Bengtsson E: Immunization of apoE-/-mice with aldehyde-modified fibronectin inhibits the development of atherosclerosis. Cardiovasc Res 2011, 91:528-536.
51. Van YH, Lee WH, Ortiz S, Lee MH, Qin HJ, Liu CP: All-trans retinoic acid inhibits type 1 diabetes by T regulatory (Treg)-dependent suppression of interferon-gamma-producing T-cells without affecting Th17 cells. Diabetes 2009, 58:146-155.
52. Boyanovsky B, Zack M, Forrest K, Webb NR: The capacity of group V sPLA2 to increase atherogenicity of ApoE-/-and LDLR-/-mouse LDL in vitro predicts its atherogenic role in vivo. Arterioscler Thromb Vasc Biol 2009, 29:532-538.
53. Yuan X, Yang X, Cai D, Mao D, Wu J, Zong L, Liu J: Intranasal immunization with chitosan/pCETP nanoparticles inhibits atherosclerosis in a rabbit model of atherosclerosis. Vaccine 2008, 26:3727-3734.
54. Ansell B, Hobbs FD: The potential for CETP inhibition to reduce cardiovascular disease risk. Curr Med Res Opin 2006, 22:2467-2478.
55. Davidson MH, Maki K, Umporowicz D, Wheeler A, Rittershaus C, Ryan U: The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 2003, 169:113-120.